StemCo Biomedical has a new name. The company is now called Aldagen.

The firm said the change reflects “more accurately the company’s focus and significant progress in the regenerative medicine field.”

“Over the past year, our efforts have resulted in numerous preclinical, clinical and regulatory milestones, which will position Aldagen as the leading regenerative medicine company,” said Ed Field, the firm’s president. “We wanted to use a name that connects regenerative medicine to our proprietary adult stem cell isolation technology based on the expression of an enzyme, aldehyde dehydrogenase. We will make several public announcements over the next three months that will reflect our progress in initiating clinical studies and generating exciting preclinical data for various therapeutic applications in regenerative medicine.”

StemCo had reflected the company’s emphasis on adult stem cell therapy.